Focus: Deva Holdings is a Turkish pharmaceutical manufacturer producing over 600 products across 13 therapeutic areas, with primary focus on generic and established drugs. The company operates as a mid-sized regional player headquartered in Istanbul.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Deva Holdings to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship product generating 80% of company revenue; generic cephalosporin antibiotic in mature market facing commodity pricing pressure.
Help build intelligence for Deva Holdings
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Deva Holdings's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Niche metabolic disorder treatment with modest revenue contribution; orphan/rare disease positioning provides some pricing resilience.
Generic immunosuppressant with established market presence; low Part D spending reflects specialist/inpatient distribution.
Proton pump inhibitor in highly competitive generic GI market with limited differentiation.
Beta-lactam/beta-lactamase inhibitor combination in crowded generic antibiotic space with commodity pricing.
Respiratory inhalation product with established clinical utility; generic competition limits pricing power.
Proton pump inhibitor in saturated OTC/generic GI market with commodity economics.
1 discontinued, 8 duplicate formulations not shown
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo+5 more products